Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Reuters recently issued a special report focusing on National Securities Corp., alleging conflicts of interest when the company’s analysts recommend certain biotech companies.
Allergan is suing Pfizer over morphine-based opioid drugs, Kadian, that Allergan acquired in December 2008. Read more if you wish to know more about this matter.
A Minnesota woman, Denise Miley, is suing Bristol-Myers Squibb and Otsuka Pharmaeutical, alleging that their Abilify (aripiprazole) for depression and anxiety, caused a gambling impulse. Her suit isn’t the only one.
As Britain’s “Brexit” from the European Union moves closer and closer, the European Medicines Agency (EMA), the equivalent to the U.S. Food and Drug Administration (FDA), temporary halted some of its activities in preparation.
Although no one really knows what President Trump will do to address high drug prices, Pfizer’s chief executive officer Ian Read said he believes it will crack down on drug rebates.
Berwyn, Pennsylvania attorneys RM Law, P.C. filed a class action lawsuit against Acadia Pharmaceuticals. The suit was filed on behalf of “all persons or entities” that bought company stock between July 17, 2014 and July 3, 2018.
After multiple suspensions, the U.S. House of Representatives overwhelmingly voted to repeal a 2.3 percent tax on medical devices that was part of the Affordable Care Act that industry representatives believed stifled innovation.
Chinese biopharmaceutical company, Changsheng Bio-Technology, is under investigation by Chinese regulators for allegedly falsifying data for a number of products.
Battered and beleaguered biotech Theranos, Inc. has settled another civil case. This time the financially strapped company settled a lawsuit filed be investors who claimed they were defrauded by the company.
After spending 14 years behind bars for sexually molesting a 10-year-old girl, famed geneticist W. French Anderson was shocked to see the leaps and bounds made by scientists in his field when he emerged from prison.